Incorporating therapeutic drug monitoring into the World Health Organization hierarchy of tuberculosis diagnostics

European Respiratory Journal

Volumn 47, Issue 6, 2016, Pages 1867-1869

  Ghimire, Samiksha ^a   Bolhuis, Mathieu S ^a   Sturkenboom, Marieke G G ^a   Akkerman, Onno W ^a   De Lange, Wiel C M ^a   Van Der Werf, Tjip S ^a   Alffenaar, Jan Willem C ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

QUINOLONE DERIVATIVE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

AREA UNDER THE CURVE; COMORBIDITY; DRIED BLOOD SPOT TESTING; DRUG EXPOSURE; DRUG MONITORING; DRUG RESISTANCE; DRUG RESPONSE; DRUG SALIVA LEVEL; HUMAN; LETTER; LIQUID CHROMATOGRAPHY; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; THIN LAYER CHROMATOGRAPHY; TUBERCULOSIS; WORLD HEALTH ORGANIZATION; DRUG SURVEILLANCE PROGRAM; MEDICATION THERAPY MANAGEMENT; ORGANIZATION AND MANAGEMENT; PROCEDURES;

ANTITUBERCULAR AGENTS; DRUG MONITORING; HUMANS; MEDICATION THERAPY MANAGEMENT; PHARMACOVIGILANCE; TUBERCULOSIS; WORLD HEALTH ORGANIZATION;

EID: 84973465872     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.00040-2016     Document Type: Letter

References (16)

1. World Health Organization (WHO). Global Tuberculosis Report 2015 (20th Edition). Geneva, WHO Press, 2015.
2. Srivastava S, Pasipanodya JG, Meek C, et al. Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability. J Infect Dis 2011; 204: 1951-1959.
3. van der Burgt EP, Sturkenboom MG, Bolhuis MS, et al. End TB with precision treatment! Eur Respir J 2016; 47: 680-682.
4. Gumbo T, Pasipanodya JG, Wash P, et al. Redefining multidrug-resistant tuberculosis based on clinical response to combination therapy. Antimicrob Agents Chemother 2014; 58: 6111-6115.
5. Daskapan A, de Lange WC, Akkerman OW, et al. The role of therapeutic drug monitoring in individualised drug dosage and exposure measurement in tuberculosis and HIV co-infection. Eur Respir J 2015; 45: 569-571.
6. Pranger AD, van Altena R, Aarnoutse RE, et al. Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience. Eur Respir J 2011; 38: 888-894.
7. Alsultan A, An G, Peloquin CA. Limited sampling strategy and target attainment analysis for levofloxacin in patients with tuberculosis. Antimicrob Agents Chemother 2015; 59: 3800-3807.
8. Alsultan A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs 2014; 74: 839-854.
9. Srivastava S, Peloquin CA, Sotgiu G, et al. Therapeutic drug management: is it the future of multidrug-resistant tuberculosis treatment? Eur Respir J 2013; 42: 1449-1453.
10. Kim HJ, Seo KA, Kim HM, et al. Simple and accurate quantitative analysis of 20 anti-tuberculosis drugs in human plasma using liquid chromatography-electrospray ionization-tandem mass spectrometry. J Pharm Biomed Anal 2015; 102: 9-16.
11. Hofman S, Bolhuis MS, Koster RA, et al. Role of therapeutic drug monitoring in pulmonary infections: use and potential for expanded use of dried blood spot samples. Bioanalysis 2015; 7: 481-495.
12. Orisakwe OE, Akunyili DN, Agbasi PU, et al. Some plasma and saliva pharmacokinetics parameters of rifampicin in the presence of pefloxacin. Am J Ther 2004; 11: 283-287.
13. Kozjek F, Šuturkova LJ, Antolič G, et al. Kinetics of 4-fluoroquinolones permeation into saliva. Biopharm Drug Dispos 1999; 20: 183-191.
14. Aarnoutse RE, Sturkenboom MG, Robijns K, et al. An interlaboratory quality control programme for the measurement of tuberculosis drugs. Eur Respir J 2015; 46: 268-271.
15. Heysell SK, Moore JL, Keller SJ, et al. Therapeutic drug monitoring for slow response to tuberculosis treatment in a state control program, Virginia, USA. Emerg Infect Dis 2010; 16: 1546-1553.
16. World Health Organization. Implementing tuberculosis diagnostics: policy framework. Geneva, WHO Press, 2015.